Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (45)

Search Parameters:
Authors = David J. Murphy

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
15 pages, 2847 KiB  
Article
Metabolomic Profiles During and After a Hypertensive Disorder of Pregnancy: The EPOCH Study
by Mark A. Hlatky, Chi-Hung Shu, Nasim Bararpour, Brenna M. Murphy, Sabina M. Sorondo, Nicholas J. Leeper, Frank Wong, David K. Stevenson, Gary M. Shaw, Marcia L. Stefanick, Heather A. Boyd, Mads Melbye, Oshra Sedan, Ronald J. Wong, Michael P. Snyder, Nima Aghaeepour and Virginia D. Winn
Int. J. Mol. Sci. 2025, 26(13), 6150; https://doi.org/10.3390/ijms26136150 - 26 Jun 2025
Viewed by 408
Abstract
Hypertensive disorders of pregnancy are associated with a higher risk of later cardiovascular disease, but the mechanistic links are unknown. We recruited two groups of women, one during pregnancy and another at least two years after delivery, including both cases (with a hypertensive [...] Read more.
Hypertensive disorders of pregnancy are associated with a higher risk of later cardiovascular disease, but the mechanistic links are unknown. We recruited two groups of women, one during pregnancy and another at least two years after delivery, including both cases (with a hypertensive disorder of pregnancy) and controls (with a normotensive pregnancy). We measured metabolites using liquid chromatography–mass spectroscopy and applied machine learning to identify metabolomic signatures at three time points: antepartum, postpartum, and mid-life. The mean ages of the pregnancy cohort (58 cases, 46 controls) and the mid-life group (71 cases, 74 controls) were 33.8 and 40.8 years, respectively. The levels of 157 metabolites differed significantly between the cases and the controls antepartum, including 19 acylcarnitines, 12 gonadal steroids, 11 glycerophospholipids, nine fatty acids, six vitamin D metabolites, and four corticosteroids. The machine learning model developed using all antepartum metabolite levels discriminated well between the cases and the controls antepartum (c-index = 0.96), postpartum (c-index = 0.63), and in mid-life (c-index = 0.60). Levels of 10,20-dihydroxyeicosanoic acid best distinguished the cases from the controls both antepartum and postpartum. These data suggest that the pattern of differences in metabolites found antepartum continues to distinguish women who had a hypertensive disorder of pregnancy from women with a normotensive pregnancy for years after delivery. Full article
(This article belongs to the Special Issue Molecular Links Between Pregnancy and Chronic Diseases)
Show Figures

Figure 1

43 pages, 3631 KiB  
Article
Genetic and Regulatory Mechanisms of Comorbidity of Anxiety, Depression and ADHD: A GWAS Meta-Meta-Analysis Through the Lens of a System Biological and Pharmacogenomic Perspective in 18.5 M Subjects
by Kai-Uwe Lewandrowski, Kenneth Blum, Alireza Sharafshah, Kyriaki Z. Thanos, Panayotis K. Thanos, Richa Zirath, Albert Pinhasov, Abdalla Bowirrat, Nicole Jafari, Foojan Zeine, Milan Makale, Colin Hanna, David Baron, Igor Elman, Edward J. Modestino, Rajendra D. Badgaiyan, Keerthy Sunder, Kevin T. Murphy, Ashim Gupta, Alex P. L. Lewandrowski, Rossano Kepler Alvim Fiorelli and Sergio Schmidtadd Show full author list remove Hide full author list
J. Pers. Med. 2025, 15(3), 103; https://doi.org/10.3390/jpm15030103 - 5 Mar 2025
Cited by 1 | Viewed by 3505
Abstract
Background: In the United States, approximately 1 in 5 children experience comorbidities with mental illness, including depression and anxiety, which lead to poor general health outcomes. Adolescents with substance use disorders exhibit high rates of co-occurring mental illness, with over 60% meeting diagnostic [...] Read more.
Background: In the United States, approximately 1 in 5 children experience comorbidities with mental illness, including depression and anxiety, which lead to poor general health outcomes. Adolescents with substance use disorders exhibit high rates of co-occurring mental illness, with over 60% meeting diagnostic criteria for another psychiatric condition in community-based treatment programs. Comorbidities are influenced by both genetic (DNA antecedents) and environmental (epigenetic) factors. Given the significant impact of psychiatric comorbidities on individuals’ lives, this study aims to uncover common mechanisms through a Genome-Wide Association Study (GWAS) meta-meta-analysis. Methods: GWAS datasets were obtained for each comorbid phenotype, followed by a GWAS meta-meta-analysis using a significance threshold of p < 5E−8 to validate the rationale behind combining all GWAS phenotypes. The combined and refined dataset was subjected to bioinformatic analyses, including Protein–Protein Interactions and Systems Biology. Pharmacogenomics (PGx) annotations for all potential genes with at least one PGx were tested, and the genes identified were combined with the Genetic Addiction Risk Severity (GARS) test, which included 10 genes and eleven Single Nucleotide Polymorphisms (SNPs). The STRING-MODEL was employed to discover novel networks and Protein–Drug interactions. Results: Autism Spectrum Disorder (ASD) was identified as the top manifestation derived from the known comorbid interaction of anxiety, depression, and attention deficit hyperactivity disorder (ADHD). The STRING-MODEL and Protein–Drug interaction analysis revealed a novel network associated with these psychiatric comorbidities. The findings suggest that these interactions are linked to the need to induce “dopamine homeostasis” as a therapeutic outcome. Conclusions: This study provides a reliable genetic and epigenetic map that could assist healthcare professionals in the therapeutic care of patients presenting with multiple psychiatric manifestations, including anxiety, depression, and ADHD. The results highlight the importance of targeting dopamine homeostasis in managing ASD linked to these comorbidities. These insights may guide future pharmacogenomic interventions to improve clinical outcomes in affected individuals. Full article
(This article belongs to the Section Omics/Informatics)
Show Figures

Figure 1

12 pages, 1463 KiB  
Communication
An Enigmatic Wild Passerine Mortality Event in the Eastern United States
by Sabrina S. Greening, Julie C. Ellis, Nicole L. Lewis, David B. Needle, Cristina M. Tato, Susan Knowles, Valerie Shearn-Bochsler, Jaimie L. Miller, Daniel A Grear, Jeffrey M. Lorch, David S. Blehert, Caitlin Burrell, Lisa A. Murphy, Erica A. Miller, C. Brandon Ogbunugafor, Andrea J. Ayala, W. Kelley Thomas, Joseph L. Sevigny, Lawrence M. Gordon, Tessa Baillargeon, Lusajo Mwakibete, Megan Kirchgessner, Christine L. Casey, Ethan Barton, Michael J. Yabsley, Eman Anis, Roderick B. Gagne, Patrice Klein, Cindy Driscoll, Chelsea A. Sykes, Robert H. Poppenga and Nicole M. Nemethadd Show full author list remove Hide full author list
Vet. Sci. 2025, 12(1), 48; https://doi.org/10.3390/vetsci12010048 - 11 Jan 2025
Viewed by 2186
Abstract
The ability to rapidly respond to wildlife health events is essential. However, such events are often unpredictable, especially with anthropogenic disturbances and climate-related environmental changes driving unforeseen threats. Many events also are short-lived and go undocumented, making it difficult to draw on lessons [...] Read more.
The ability to rapidly respond to wildlife health events is essential. However, such events are often unpredictable, especially with anthropogenic disturbances and climate-related environmental changes driving unforeseen threats. Many events also are short-lived and go undocumented, making it difficult to draw on lessons learned from past investigations. We report on the response to a mortality event observed predominantly in wild passerines in the eastern United States. The event began in May 2021 when wildlife rehabilitators and private citizens reported large numbers of sick and dead juvenile birds, mostly presenting as single cases with neurologic signs and/or ocular and periocular lesions. Early efforts by rehabilitators, veterinarians, state and federal wildlife agencies, and universities helped gather public reports and fuel rapid responses by government agencies. Collective efforts included live bird and carcass collections; submission to diagnostic laboratories and evaluation; information sharing; and coordinated messaging to stakeholders and interested parties. Extensive diagnostic evaluations failed to identify a causative pathogen or other etiology, although congruent results across laboratories have helped drive further investigation into alternative causes, such as nutritional deficiencies. This report highlights the strengths of a multi-agency, interdisciplinary investigation while exposing the need for an operational framework with approaches and resources dedicated to wildlife health. Full article
(This article belongs to the Special Issue Wildlife Health and Disease in Conservation)
Show Figures

Graphical abstract

13 pages, 2587 KiB  
Article
A Simplified Model of Adenine-Induced Chronic Kidney Disease Using SKH1 Mice
by Benjamin W. French, Joshua D. Breidenbach, Shereen G. Yassine, Bella Z. Khatib-Shahidi, Sara Kazmi, Caitlin M. Murphy, Humza S. Bashir, Evan M. Benson, Bivek Timalsina, Upasana Shrestha, Dhilhani Faleel, Satkeerth Boyapalli, Prabhatchandra Dube, Apurva Lad, Irum Syed, Deepak Malhotra, Amira Gohara, David J. Kennedy and Steven T. Haller
Cells 2024, 13(24), 2117; https://doi.org/10.3390/cells13242117 - 20 Dec 2024
Cited by 1 | Viewed by 2504
Abstract
Commonly used adenine-induced chronic kidney disease (CKD) murine models often employ C57BL/6 mice; however, this strain has inherent limitations due to its natural resistance to developing key pathological features of CKD, such as tubulointerstitial fibrosis and inflammation. There have been attempts to overcome [...] Read more.
Commonly used adenine-induced chronic kidney disease (CKD) murine models often employ C57BL/6 mice; however, this strain has inherent limitations due to its natural resistance to developing key pathological features of CKD, such as tubulointerstitial fibrosis and inflammation. There have been attempts to overcome these barriers by using multiple concentrations of adenine-supplemented diets or by performing prolonged experiments up to 20 weeks. Here, we demonstrate that SKH1 Elite mice develop clinically relevant CKD phenotypes (e.g., polyuria, proteinuria, inflammation, and renal fibrosis) over the course of only 6 weeks of low-dose (0.15%) adenine supplementation. As a docile, immunocompetent, and hairless strain, SKH1 Elite mice offer several logistical advantages over C57BL/6 mice, including ease of handling and the ability to study dermal conditions, which are often secondary to CKD. Full article
(This article belongs to the Special Issue Cellular and Molecular Basis in Chronic Kidney Disease)
Show Figures

Figure 1

17 pages, 659 KiB  
Review
The Role of Yeast in the Valorisation of Food Waste
by Laura Murphy and David J. O’Connell
Fermentation 2024, 10(11), 583; https://doi.org/10.3390/fermentation10110583 - 13 Nov 2024
Cited by 1 | Viewed by 2494
Abstract
The implementation of the circular bioeconomy is now widely accepted as a critical step towards reducing the environmental burden of industrial waste and reducing the impact of this waste on climate change. The valorisation of waste using microorganisms is an attractive and fast-developing [...] Read more.
The implementation of the circular bioeconomy is now widely accepted as a critical step towards reducing the environmental burden of industrial waste and reducing the impact of this waste on climate change. The valorisation of waste using microorganisms is an attractive and fast-developing strategy capable of achieving meaningful improvements in the sustainability of the biotechnology industry. Yeasts are a powerful chassis for developing valorisation strategies and key opportunities. Thus, this study examines how waste from the food sector can be effectively targeted for valorisation by yeast. Yeasts themselves are critically important elements in the production of food and brewing, and thus, the valorisation of waste from these processes is further reviewed. Policy and regulatory challenges that may impact the feasibility of industrial applications of yeast systems in the valorisation of food waste streams are also discussed. Full article
(This article belongs to the Special Issue Food Wastes: Feedstock for Value-Added Products: 5th Edition)
Show Figures

Graphical abstract

18 pages, 2449 KiB  
Article
Decreased Circulating Gonadotropin-Releasing Hormone Associated with Keratoconus
by Paulina Escandon, Alexander J. Choi, Steve Mabry, Sarah E. Nicholas, Rebecca L. Cunningham, Liam Redden, David A. Murphy, Kamran M. Riaz, Tina B. McKay and Dimitrios Karamichos
Cells 2024, 13(20), 1704; https://doi.org/10.3390/cells13201704 - 15 Oct 2024
Cited by 1 | Viewed by 1553
Abstract
Keratoconus (KC) is a corneal thinning dystrophy that leads to visual impairment. While the cause of KC remains poorly understood, changes in sex hormone levels have been correlated with KC development. This study investigated circulating gonadotropin-releasing hormone (GnRH) in control and KC subjects [...] Read more.
Keratoconus (KC) is a corneal thinning dystrophy that leads to visual impairment. While the cause of KC remains poorly understood, changes in sex hormone levels have been correlated with KC development. This study investigated circulating gonadotropin-releasing hormone (GnRH) in control and KC subjects to determine if this master hormone regulator is linked to the KC pathology. Plasma and saliva were collected from KC subjects (n = 227 and n = 274, respectively) and non-KC controls (n = 58 and n = 101, respectively), in concert with patient demographics and clinical features. GnRH levels in both plasma and saliva were significantly lower in KC subjects compared to controls. This finding was retained in plasma when subjects were stratified based on age, sex, and KC severity. Control and KC corneal fibroblasts (HKCs) stimulated with recombinant GnRH protein in vitro revealed significantly increased luteinizing hormone receptor by HKCs and reduced expression of α-smooth muscle actin with treatment suggesting that GnRH may modulate hormonal and fibrotic responses in the KC corneal stroma. Further studies are needed to reveal the role of the hypothalamic–pituitary–gonadal axis in the onset and progression of KC and to explore this pathway as a novel therapeutic target. Full article
(This article belongs to the Special Issue Cell Therapeutics for Corneal Diseases)
Show Figures

Graphical abstract

45 pages, 30346 KiB  
Article
Performance of a Modular Ton-Scale Pixel-Readout Liquid Argon Time Projection Chamber
by A. Abed Abud, B. Abi, R. Acciarri, M. A. Acero, M. R. Adames, G. Adamov, M. Adamowski, D. Adams, M. Adinolfi, C. Adriano, A. Aduszkiewicz, J. Aguilar, B. Aimard, F. Akbar, K. Allison, S. Alonso Monsalve, M. Alrashed, A. Alton, R. Alvarez, T. Alves, H. Amar, P. Amedo, J. Anderson, D. A. Andrade, C. Andreopoulos, M. Andreotti, M. P. Andrews, F. Andrianala, S. Andringa, N. Anfimov, A. Ankowski, M. Antoniassi, M. Antonova, A. Antoshkin, A. Aranda-Fernandez, L. Arellano, E. Arrieta Diaz, M. A. Arroyave, J. Asaadi, A. Ashkenazi, D. Asner, L. Asquith, E. Atkin, D. Auguste, A. Aurisano, V. Aushev, D. Autiero, F. Azfar, A. Back, H. Back, J. J. Back, I. Bagaturia, L. Bagby, N. Balashov, S. Balasubramanian, P. Baldi, W. Baldini, J. Baldonedo, B. Baller, B. Bambah, R. Banerjee, F. Barao, G. Barenboim, P. B̃arham Alzás, G. J. Barker, W. Barkhouse, G. Barr, J. Barranco Monarca, A. Barros, N. Barros, D. Barrow, J. L. Barrow, A. Basharina-Freshville, A. Bashyal, V. Basque, C. Batchelor, L. Bathe-Peters, J. B. R. Battat, F. Battisti, F. Bay, M. C. Q. Bazetto, J. L. L. Bazo Alba, J. F. Beacom, E. Bechetoille, B. Behera, E. Belchior, G. Bell, L. Bellantoni, G. Bellettini, V. Bellini, O. Beltramello, N. Benekos, C. Benitez Montiel, D. Benjamin, F. Bento Neves, J. Berger, S. Berkman, J. Bernal, P. Bernardini, A. Bersani, S. Bertolucci, M. Betancourt, A. Betancur Rodríguez, A. Bevan, Y. Bezawada, A. T. Bezerra, T. J. Bezerra, A. Bhat, V. Bhatnagar, J. Bhatt, M. Bhattacharjee, M. Bhattacharya, S. Bhuller, B. Bhuyan, S. Biagi, J. Bian, K. Biery, B. Bilki, M. Bishai, A. Bitadze, A. Blake, F. D. Blaszczyk, G. C. Blazey, E. Blucher, J. Bogenschuetz, J. Boissevain, S. Bolognesi, T. Bolton, L. Bomben, M. Bonesini, C. Bonilla-Diaz, F. Bonini, A. Booth, F. Boran, S. Bordoni, R. Borges Merlo, A. Borkum, N. Bostan, J. Bracinik, D. Braga, B. Brahma, D. Brailsford, F. Bramati, A. Branca, A. Brandt, J. Bremer, C. Brew, S. J. Brice, V. Brio, C. Brizzolari, C. Bromberg, J. Brooke, A. Bross, G. Brunetti, M. Brunetti, N. Buchanan, H. Budd, J. Buergi, D. Burgardt, S. Butchart, G. Caceres V., I. Cagnoli, T. Cai, R. Calabrese, J. Calcutt, M. Calin, L. Calivers, E. Calvo, A. Caminata, A. F. Camino, W. Campanelli, A. Campani, A. Campos Benitez, N. Canci, J. Capó, I. Caracas, D. Caratelli, D. Carber, J. M. Carceller, G. Carini, B. Carlus, M. F. Carneiro, P. Carniti, I. Caro Terrazas, H. Carranza, N. Carrara, L. Carroll, T. Carroll, A. Carter, E. Casarejos, D. Casazza, J. F. Castaño Forero, F. A. Castaño, A. Castillo, C. Castromonte, E. Catano-Mur, C. Cattadori, F. Cavalier, F. Cavanna, S. Centro, G. Cerati, C. Cerna, A. Cervelli, A. Cervera Villanueva, K. Chakraborty, S. Chakraborty, M. Chalifour, A. Chappell, N. Charitonidis, A. Chatterjee, H. Chen, M. Chen, W. C. Chen, Y. Chen, Z. Chen-Wishart, D. Cherdack, C. Chi, R. Chirco, N. Chitirasreemadam, K. Cho, S. Choate, D. Chokheli, P. S. Chong, B. Chowdhury, D. Christian, A. Chukanov, M. Chung, E. Church, M. F. Cicala, M. Cicerchia, V. Cicero, R. Ciolini, P. Clarke, G. Cline, T. E. Coan, A. G. Cocco, J. A. B. Coelho, A. Cohen, J. Collazo, J. Collot, E. Conley, J. M. Conrad, M. Convery, S. Copello, P. Cova, C. Cox, L. Cremaldi, L. Cremonesi, J. I. Crespo-Anadón, M. Crisler, E. Cristaldo, J. Crnkovic, G. Crone, R. Cross, A. Cudd, C. Cuesta, Y. Cui, F. Curciarello, D. Cussans, J. Dai, O. Dalager, R. Dallavalle, W. Dallaway, H. da Motta, Z. A. Dar, R. Darby, L. Da Silva Peres, Q. David, G. S. Davies, S. Davini, J. Dawson, R. De Aguiar, P. De Almeida, P. Debbins, I. De Bonis, M. P. Decowski, A. de Gouvêa, P. C. De Holanda, I. L. De Icaza Astiz, P. De Jong, P. Del Amo Sanchez, A. De la Torre, G. De Lauretis, A. Delbart, D. Delepine, M. Delgado, A. Dell’Acqua, G. Delle Monache, N. Delmonte, P. De Lurgio, R. Demario, G. De Matteis, J. R. T. de Mello Neto, D. M. DeMuth, S. Dennis, C. Densham, P. Denton, G. W. Deptuch, A. De Roeck, V. De Romeri, J. P. Detje, J. Devine, R. Dharmapalan, M. Dias, A. Diaz, J. S. Díaz, F. Díaz, F. Di Capua, A. Di Domenico, S. Di Domizio, S. Di Falco, L. Di Giulio, P. Ding, L. Di Noto, E. Diociaiuti, C. Distefano, R. Diurba, M. Diwan, Z. Djurcic, D. Doering, S. Dolan, F. Dolek, M. J. Dolinski, D. Domenici, L. Domine, S. Donati, Y. Donon, S. Doran, D. Douglas, T. A. Doyle, A. Dragone, F. Drielsma, L. Duarte, D. Duchesneau, K. Duffy, K. Dugas, P. Dunne, B. Dutta, H. Duyang, D. A. Dwyer, A. S. Dyshkant, S. Dytman, M. Eads, A. Earle, S. Edayath, D. Edmunds, J. Eisch, P. Englezos, A. Ereditato, T. Erjavec, C. O. Escobar, J. J. Evans, E. Ewart, A. C. Ezeribe, K. Fahey, L. Fajt, A. Falcone, M. Fani’, C. Farnese, S. Farrell, Y. Farzan, D. Fedoseev, J. Felix, Y. Feng, E. Fernandez-Martinez, G. Ferry, L. Fields, P. Filip, A. Filkins, F. Filthaut, R. Fine, G. Fiorillo, M. Fiorini, S. Fogarty, W. Foreman, J. Fowler, J. Franc, K. Francis, D. Franco, J. Franklin, J. Freeman, J. Fried, A. Friedland, S. Fuess, I. K. Furic, K. Furman, A. P. Furmanski, R. Gaba, A. Gabrielli, A. M. Gago, F. Galizzi, H. Gallagher, A. Gallas, N. Gallice, V. Galymov, E. Gamberini, T. Gamble, F. Ganacim, R. Gandhi, S. Ganguly, F. Gao, S. Gao, D. Garcia-Gamez, M. Á. García-Peris, F. Gardim, S. Gardiner, D. Gastler, A. Gauch, J. Gauvreau, P. Gauzzi, S. Gazzana, G. Ge, N. Geffroy, B. Gelli, S. Gent, L. Gerlach, Z. Ghorbani-Moghaddam, T. Giammaria, D. Gibin, I. Gil-Botella, S. Gilligan, A. Gioiosa, S. Giovannella, C. Girerd, A. K. Giri, C. Giugliano, V. Giusti, D. Gnani, O. Gogota, S. Gollapinni, K. Gollwitzer, R. A. Gomes, L. V. Gomez Bermeo, L. S. Gomez Fajardo, F. Gonnella, D. Gonzalez-Diaz, M. Gonzalez-Lopez, M. C. Goodman, S. Goswami, C. Gotti, J. Goudeau, E. Goudzovski, C. Grace, E. Gramellini, R. Gran, E. Granados, P. Granger, C. Grant, D. R. Gratieri, G. Grauso, P. Green, S. Greenberg, J. Greer, W. C. Griffith, F. T. Groetschla, K. Grzelak, L. Gu, W. Gu, V. Guarino, M. Guarise, R. Guenette, E. Guerard, M. Guerzoni, D. Guffanti, A. Guglielmi, B. Guo, Y. Guo, A. Gupta, V. Gupta, G. Gurung, D. Gutierrez, P. Guzowski, M. M. Guzzo, S. Gwon, A. Habig, H. Hadavand, L. Haegel, R. Haenni, L. Hagaman, A. Hahn, J. Haiston, J. Hakenmueller, T. Hamernik, P. Hamilton, J. Hancock, F. Happacher, D. A. Harris, J. Hartnell, T. Hartnett, J. Harton, T. Hasegawa, C. Hasnip, R. Hatcher, K. Hayrapetyan, J. Hays, E. Hazen, M. He, A. Heavey, K. M. Heeger, J. Heise, S. Henry, M. A. Hernandez Morquecho, K. Herner, V. Hewes, A. Higuera, C. Hilgenberg, S. J. Hillier, A. Himmel, E. Hinkle, L. R. Hirsch, J. Ho, J. Hoff, A. Holin, T. Holvey, E. Hoppe, S. Horiuchi, G. A. Horton-Smith, M. Hostert, T. Houdy, B. Howard, R. Howell, I. Hristova, M. S. Hronek, J. Huang, R. G. Huang, Z. Hulcher, M. Ibrahim, G. Iles, N. Ilic, A. M. Iliescu, R. Illingworth, G. Ingratta, A. Ioannisian, B. Irwin, L. Isenhower, M. Ismerio Oliveira, R. Itay, C. M. Jackson, V. Jain, E. James, W. Jang, B. Jargowsky, D. Jena, I. Jentz, X. Ji, C. Jiang, J. Jiang, L. Jiang, A. Jipa, F. R. Joaquim, W. Johnson, C. Jollet, B. Jones, R. Jones, D. José Fernández, N. Jovancevic, M. Judah, C. K. Jung, T. Junk, Y. Jwa, M. Kabirnezhad, A. C. Kaboth, I. Kadenko, I. Kakorin, A. Kalitkina, D. Kalra, M. Kandemir, D. M. Kaplan, G. Karagiorgi, G. Karaman, A. Karcher, Y. Karyotakis, S. Kasai, S. P. Kasetti, L. Kashur, I. Katsioulas, A. Kauther, N. Kazaryan, L. Ke, E. Kearns, P. T. Keener, K. J. Kelly, E. Kemp, O. Kemularia, Y. Kermaidic, W. Ketchum, S. H. Kettell, M. Khabibullin, N. Khan, A. Khvedelidze, D. Kim, J. Kim, M. Kim, B. King, B. Kirby, M. Kirby, A. Kish, J. Klein, J. Kleykamp, A. Klustova, T. Kobilarcik, L. Koch, K. Koehler, L. W. Koerner, D. H. Koh, L. Kolupaeva, D. Korablev, M. Kordosky, T. Kosc, U. Kose, V. A. Kostelecký, K. Kothekar, I. Kotler, M. Kovalcuk, V. Kozhukalov, W. Krah, R. Kralik, M. Kramer, L. Kreczko, F. Krennrich, I. Kreslo, T. Kroupova, S. Kubota, M. Kubu, Y. Kudenko, V. A. Kudryavtsev, G. Kufatty, S. Kuhlmann, J. Kumar, P. Kumar, S. Kumaran, P. Kunze, J. Kunzmann, R. Kuravi, N. Kurita, C. Kuruppu, V. Kus, T. Kutter, J. Kvasnicka, T. Labree, T. Lackey, A. Lambert, B. J. Land, C. E. Lane, N. Lane, K. Lang, T. Langford, M. Langstaff, F. Lanni, O. Lantwin, J. Larkin, P. Lasorak, D. Last, A. Laudrain, A. Laundrie, G. Laurenti, E. Lavaut, A. Lawrence, P. Laycock, I. Lazanu, M. Lazzaroni, T. Le, S. Leardini, J. Learned, T. LeCompte, C. Lee, V. Legin, G. Lehmann Miotto, R. Lehnert, M. A. Leigui de Oliveira, M. Leitner, D. Leon Silverio, L. M. Lepin, J.-Y. Li, S. W. Li, Y. Li, H. Liao, C. S. Lin, D. Lindebaum, S. Linden, R. A. Lineros, J. Ling, A. Lister, B. R. Littlejohn, H. Liu, J. Liu, Y. Liu, S. Lockwitz, M. Lokajicek, I. Lomidze, K. Long, T. V. Lopes, J. Lopez, I. López de Rego, N. López-March, T. Lord, J. M. LoSecco, W. C. Louis, A. Lozano Sanchez, X.-G. Lu, K. B. Luk, B. Lunday, X. Luo, E. Luppi, J. Maalmi, D. MacFarlane, A. A. Machado, P. Machado, C. T. Macias, J. R. Macier, M. MacMahon, A. Maddalena, A. Madera, P. Madigan, S. Magill, C. Magueur, K. Mahn, A. Maio, A. Major, K. Majumdar, M. Man, R. C. Mandujano, J. Maneira, S. Manly, A. Mann, K. Manolopoulos, M. Manrique Plata, S. Manthey Corchado, V. N. Manyam, M. Marchan, A. Marchionni, W. Marciano, D. Marfatia, C. Mariani, J. Maricic, F. Marinho, A. D. Marino, T. Markiewicz, F. Das Chagas Marques, C. Marquet, D. Marsden, M. Marshak, C. M. Marshall, J. Marshall, L. Martina, J. Martín-Albo, N. Martinez, D. A. Martinez Caicedo, F. Martínez López, P. Martínez Miravé, S. Martynenko, V. Mascagna, C. Massari, A. Mastbaum, F. Matichard, S. Matsuno, G. Matteucci, J. Matthews, C. Mauger, N. Mauri, K. Mavrokoridis, I. Mawby, R. Mazza, A. Mazzacane, T. McAskill, N. McConkey, K. S. McFarland, C. McGrew, A. McNab, L. Meazza, V. C. N. Meddage, B. Mehta, P. Mehta, P. Melas, O. Mena, H. Mendez, P. Mendez, D. P. Méndez, A. Menegolli, G. Meng, A. C. E. A. Mercuri, A. Meregaglia, M. D. Messier, S. Metallo, J. Metcalf, W. Metcalf, M. Mewes, H. Meyer, T. Miao, A. Miccoli, G. Michna, V. Mikola, R. Milincic, F. Miller, G. Miller, W. Miller, O. Mineev, A. Minotti, L. Miralles, O. G. Miranda, C. Mironov, S. Miryala, S. Miscetti, C. S. Mishra, S. R. Mishra, A. Mislivec, M. Mitchell, D. Mladenov, I. Mocioiu, A. Mogan, N. Moggi, R. Mohanta, T. A. Mohayai, N. Mokhov, J. Molina, L. Molina Bueno, E. Montagna, A. Montanari, C. Montanari, D. Montanari, D. Montanino, L. M. Montaño Zetina, M. Mooney, A. F. Moor, Z. Moore, D. Moreno, O. Moreno-Palacios, L. Morescalchi, D. Moretti, R. Moretti, C. Morris, C. Mossey, M. Mote, C. A. Moura, G. Mouster, W. Mu, L. Mualem, J. Mueller, M. Muether, F. Muheim, A. Muir, M. Mulhearn, D. Munford, L. J. Munteanu, H. Muramatsu, J. Muraz, M. Murphy, T. Murphy, J. Muse, A. Mytilinaki, J. Nachtman, Y. Nagai, S. Nagu, R. Nandakumar, D. Naples, S. Narita, A. Nath, A. Navrer-Agasson, N. Nayak, M. Nebot-Guinot, A. Nehm, J. K. Nelson, O. Neogi, J. Nesbit, M. Nessi, D. Newbold, M. Newcomer, R. Nichol, F. Nicolas-Arnaldos, A. Nikolica, J. Nikolov, E. Niner, K. Nishimura, A. Norman, A. Norrick, P. Novella, J. A. Nowak, M. Oberling, J. P. Ochoa-Ricoux, S. Oh, S. B. Oh, A. Olivier, A. Olshevskiy, T. Olson, Y. Onel, Y. Onishchuk, A. Oranday, M. Osbiston, J. A. Osorio Vélez, L. Otiniano Ormachea, J. Ott, L. Pagani, G. Palacio, O. Palamara, S. Palestini, J. M. Paley, M. Pallavicini, C. Palomares, S. Pan, P. Panda, W. Panduro Vazquez, E. Pantic, V. Paolone, V. Papadimitriou, R. Papaleo, A. Papanestis, D. Papoulias, S. Paramesvaran, A. Paris, S. Parke, E. Parozzi, S. Parsa, Z. Parsa, S. Parveen, M. Parvu, D. Pasciuto, S. Pascoli, L. Pasqualini, J. Pasternak, C. Patrick, L. Patrizii, R. B. Patterson, T. Patzak, A. Paudel, L. Paulucci, Z. Pavlovic, G. Pawloski, D. Payne, V. Pec, E. Pedreschi, S. J. M. Peeters, W. Pellico, A. Pena Perez, E. Pennacchio, A. Penzo, O. L. G. Peres, Y. F. Perez Gonzalez, L. Pérez-Molina, C. Pernas, J. Perry, D. Pershey, G. Pessina, G. Petrillo, C. Petta, R. Petti, M. Pfaff, V. Pia, L. Pickering, F. Pietropaolo, V. L. Pimentel, G. Pinaroli, J. Pinchault, K. Pitts, K. Plows, R. Plunkett, C. Pollack, T. Pollman, D. Polo-Toledo, F. Pompa, X. Pons, N. Poonthottathil, V. Popov, F. Poppi, J. Porter, M. Potekhin, R. Potenza, J. Pozimski, M. Pozzato, T. Prakash, C. Pratt, M. Prest, F. Psihas, D. Pugnere, X. Qian, J. L. Raaf, V. Radeka, J. Rademacker, B. Radics, A. Rafique, E. Raguzin, M. Rai, S. Rajagopalan, M. Rajaoalisoa, I. Rakhno, L. Rakotondravohitra, L. Ralte, M. A. Ramirez Delgado, B. Ramson, A. Rappoldi, G. Raselli, P. Ratoff, R. Ray, H. Razafinime, E. M. Rea, J. S. Real, B. Rebel, R. Rechenmacher, M. Reggiani-Guzzo, J. Reichenbacher, S. D. Reitzner, H. Rejeb Sfar, E. Renner, A. Renshaw, S. Rescia, F. Resnati, D. Restrepo, C. Reynolds, M. Ribas, S. Riboldi, C. Riccio, G. Riccobene, J. S. Ricol, M. Rigan, E. V. Rincón, A. Ritchie-Yates, S. Ritter, D. Rivera, R. Rivera, A. Robert, J. L. Rocabado Rocha, L. Rochester, M. Roda, P. Rodrigues, M. J. Rodriguez Alonso, J. Rodriguez Rondon, S. Rosauro-Alcaraz, P. Rosier, D. Ross, M. Rossella, M. Rossi, M. Ross-Lonergan, N. Roy, P. Roy, C. Rubbia, A. Ruggeri, G. Ruiz Ferreira, B. Russell, D. Ruterbories, A. Rybnikov, A. Saa-Hernandez, R. Saakyan, S. Sacerdoti, S. K. Sahoo, N. Sahu, P. Sala, N. Samios, O. Samoylov, M. C. Sanchez, A. Sánchez Bravo, P. Sanchez-Lucas, V. Sandberg, D. A. Sanders, S. Sanfilippo, D. Sankey, D. Santoro, N. Saoulidou, P. Sapienza, C. Sarasty, I. Sarcevic, I. Sarra, G. Savage, V. Savinov, G. Scanavini, A. Scaramelli, A. Scarff, T. Schefke, H. Schellman, S. Schifano, P. Schlabach, D. Schmitz, A. W. Schneider, K. Scholberg, A. Schukraft, B. Schuld, A. Segade, E. Segreto, A. Selyunin, C. R. Senise, J. Sensenig, M. H. Shaevitz, P. Shanahan, P. Sharma, R. Kumar, K. Shaw, T. Shaw, K. Shchablo, J. Shen, C. Shepherd-Themistocleous, A. Sheshukov, W. Shi, S. Shin, S. Shivakoti, I. Shoemaker, D. Shooltz, R. Shrock, B. Siddi, M. Siden, J. Silber, L. Simard, J. Sinclair, G. Sinev, Jaydip Singh, J. Singh, L. Singh, P. Singh, V. Singh, S. Singh Chauhan, R. Sipos, C. Sironneau, G. Sirri, K. Siyeon, K. Skarpaas, J. Smedley, E. Smith, J. Smith, P. Smith, J. Smolik, M. Smy, M. Snape, E. L. Snider, P. Snopok, D. Snowden-Ifft, M. Soares Nunes, H. Sobel, M. Soderberg, S. Sokolov, C. J. Solano Salinas, S. Söldner-Rembold, S. R. Soleti, N. Solomey, V. Solovov, W. E. Sondheim, M. Sorel, A. Sotnikov, J. Soto-Oton, A. Sousa, K. Soustruznik, F. Spinella, J. Spitz, N. J. C. Spooner, K. Spurgeon, D. Stalder, M. Stancari, L. Stanco, J. Steenis, R. Stein, H. M. Steiner, A. F. Steklain Lisbôa, A. Stepanova, J. Stewart, B. Stillwell, J. Stock, F. Stocker, T. Stokes, M. Strait, T. Strauss, L. Strigari, A. Stuart, J. G. Suarez, J. Subash, A. Surdo, L. Suter, C. M. Sutera, K. Sutton, Y. Suvorov, R. Svoboda, S. K. Swain, B. Szczerbinska, A. M. Szelc, A. Sztuc, A. Taffara, N. Talukdar, J. Tamara, H. A. Tanaka, S. Tang, N. Taniuchi, A. M. Tapia Casanova, B. Tapia Oregui, A. Tapper, S. Tariq, E. Tarpara, E. Tatar, R. Tayloe, D. Tedeschi, A. M. Teklu, J. Tena Vidal, P. Tennessen, M. Tenti, K. Terao, F. Terranova, G. Testera, T. Thakore, A. Thea, A. Thiebault, S. Thomas, A. Thompson, C. Thorn, S. C. Timm, E. Tiras, V. Tishchenko, N. Todorović, L. Tomassetti, A. Tonazzo, D. Torbunov, M. Torti, M. Tortola, F. Tortorici, N. Tosi, D. Totani, M. Toups, C. Touramanis, D. Tran, R. Travaglini, J. Trevor, E. Triller, S. Trilov, J. Truchon, D. Truncali, W. H. Trzaska, Y. Tsai, Y.-T. Tsai, Z. Tsamalaidze, K. V. Tsang, N. Tsverava, S. Z. Tu, S. Tufanli, C. Tunnell, J. Turner, M. Tuzi, J. Tyler, E. Tyley, M. Tzanov, M. A. Uchida, J. Ureña González, J. Urheim, T. Usher, H. Utaegbulam, S. Uzunyan, M. R. Vagins, P. Vahle, S. Valder, G. A. Valdiviesso, E. Valencia, R. Valentim, Z. Vallari, E. Vallazza, J. W. F. Valle, R. Van Berg, R. G. Van de Water, D. V. Forero, A. Vannozzi, M. Van Nuland-Troost, F. Varanini, D. Vargas Oliva, S. Vasina, N. Vaughan, K. Vaziri, A. Vázquez-Ramos, J. Vega, S. Ventura, A. Verdugo, S. Vergani, M. Verzocchi, K. Vetter, M. Vicenzi, H. Vieira de Souza, C. Vignoli, C. Vilela, E. Villa, S. Viola, B. Viren, A. Vizcaya-Hernandez, T. Vrba, Q. Vuong, A. V. Waldron, M. Wallbank, J. Walsh, T. Walton, H. Wang, J. Wang, L. Wang, M. H. L. S. Wang, X. Wang, Y. Wang, K. Warburton, D. Warner, L. Warsame, M. O. Wascko, D. Waters, A. Watson, K. Wawrowska, A. Weber, C. M. Weber, M. Weber, H. Wei, A. Weinstein, H. Wenzel, S. Westerdale, M. Wetstein, K. Whalen, J. Whilhelmi, A. White, A. White, L. H. Whitehead, D. Whittington, M. J. Wilking, A. Wilkinson, C. Wilkinson, F. Wilson, R. J. Wilson, P. Winter, W. Wisniewski, J. Wolcott, J. Wolfs, T. Wongjirad, A. Wood, K. Wood, E. Worcester, M. Worcester, M. Wospakrik, K. Wresilo, C. Wret, S. Wu, W. Wu, W. Wu, M. Wurm, J. Wyenberg, Y. Xiao, I. Xiotidis, B. Yaeggy, N. Yahlali, E. Yandel, K. Yang, T. Yang, A. Yankelevich, N. Yershov, K. Yonehara, T. Young, B. Yu, H. Yu, J. Yu, Y. Yu, W. Yuan, R. Zaki, J. Zalesak, L. Zambelli, B. Zamorano, A. Zani, O. Zapata, L. Zazueta, G. P. Zeller, J. Zennamo, K. Zeug, C. Zhang, S. Zhang, M. Zhao, E. Zhivun, E. D. Zimmerman, S. Zucchelli, J. Zuklin, V. Zutshi, R. Zwaska and on behalf of the DUNE Collaborationadd Show full author list remove Hide full author list
Instruments 2024, 8(3), 41; https://doi.org/10.3390/instruments8030041 - 11 Sep 2024
Cited by 4 | Viewed by 3777
Abstract
The Module-0 Demonstrator is a single-phase 600 kg liquid argon time projection chamber operated as a prototype for the DUNE liquid argon near detector. Based on the ArgonCube design concept, Module-0 features a novel 80k-channel pixelated charge readout and advanced high-coverage photon detection [...] Read more.
The Module-0 Demonstrator is a single-phase 600 kg liquid argon time projection chamber operated as a prototype for the DUNE liquid argon near detector. Based on the ArgonCube design concept, Module-0 features a novel 80k-channel pixelated charge readout and advanced high-coverage photon detection system. In this paper, we present an analysis of an eight-day data set consisting of 25 million cosmic ray events collected in the spring of 2021. We use this sample to demonstrate the imaging performance of the charge and light readout systems as well as the signal correlations between the two. We also report argon purity and detector uniformity measurements and provide comparisons to detector simulations. Full article
Show Figures

Figure 1

18 pages, 3650 KiB  
Article
Impaired Upper Airway Muscle Function with Excessive or Deficient Dietary Intake of Selenium in Rats
by David P. Burns, Sarah E. Drummond, Stefanie Wölfel, Kevin H. Murphy, Joanna Szpunar, Ken D. O’Halloran and John J. Mackrill
Antioxidants 2024, 13(9), 1080; https://doi.org/10.3390/antiox13091080 - 4 Sep 2024
Viewed by 1423
Abstract
Obstructive sleep apnoea (OSA) involves impaired upper airway muscle function and is linked to several pathologies including systemic hypertension, daytime somnolence and cognitive decline. Selenium is an essential micronutrient that exerts many of its effects through selenoproteins. Evidence indicates that either deficient or [...] Read more.
Obstructive sleep apnoea (OSA) involves impaired upper airway muscle function and is linked to several pathologies including systemic hypertension, daytime somnolence and cognitive decline. Selenium is an essential micronutrient that exerts many of its effects through selenoproteins. Evidence indicates that either deficient or excessive dietary selenium intake can result in impaired muscle function, termed nutritional myopathy. To investigate the effects of selenium on an upper airway muscle, the sternohyoid, rats were fed on diets containing deficient, normal (0.5 ppm sodium selenite) or excessive (5 ppm selenite) selenium for a period of two weeks. Sternohyoid contractile function was assessed ex vivo. Serum selenium levels and activity of the glutathione antioxidant system were determined by biochemical assays. The abundance of three key muscle selenoproteins (selenoproteins -N, -S and -W (SELENON, SELENOS and SELENOW)) in sternohyoid muscle were quantified by immunoblotting. Levels of these selenoproteins were also compared between rats exposed to chronic intermittent hypoxia, a model of OSA, and sham treated animals. Although having no detectable effect on selected organ masses and whole-body weight, either selenium-deficient or -excessive diets severely impaired sternohyoid contractile function. These changes did not involve altered fibre size distribution. These dietary interventions resulted in corresponding changes in serum selenium concentrations but did not alter the activity of glutathione-dependent antioxidant systems in sternohyoid muscle. Excess dietary selenium increased the abundance of SELENOW protein in sternohyoid muscles but had no effect on SELENON or SELENOS. In contrast, chronic intermittent hypoxia increased SELENON, decreased SELENOW and had no significant effect on SELENOS in sternohyoid muscle. These findings indicate that two-week exposure to selenium-deficient or -excessive diets drastically impaired upper airway muscle function. In the sternohyoid, SELENON, SELENOS and SELENOW proteins show distinct alterations in level following exposure to different dietary selenium intakes, or to chronic intermittent hypoxia. Understanding how alterations in Se and selenoproteins impact sternohyoid muscle function has the potential to be translated into new therapies for prevention or treatment of OSA. Full article
(This article belongs to the Section Antioxidant Enzyme Systems)
Show Figures

Figure 1

13 pages, 1679 KiB  
Article
Valorisation of Spent Yeast Fermentation Media through Compositional-Analysis-Directed Supplementation
by Laura Murphy, Ciara D. Lynch and David J. O’Connell
Appl. Microbiol. 2024, 4(2), 959-971; https://doi.org/10.3390/applmicrobiol4020065 - 12 Jun 2024
Cited by 1 | Viewed by 2537
Abstract
Spent fermentation media from bioprocessing represent a significant waste stream, and interest in recycling them as part of the developing circular bioeconomy is growing. The potential to reuse yeast spent culture media (YSM) to feed secondary bacterial fermentations producing recombinant protein was investigated [...] Read more.
Spent fermentation media from bioprocessing represent a significant waste stream, and interest in recycling them as part of the developing circular bioeconomy is growing. The potential to reuse yeast spent culture media (YSM) to feed secondary bacterial fermentations producing recombinant protein was investigated in this study. Elemental and amino acid compositional analysis using inductively coupled plasma mass spectrometry (ICP-MS) and LC-MS/MS identified significant differences in the concentrations of 6 elements and 18/20 amino acids in YSM compared with rich microbiological media (LB). Restoration of levels of magnesium and sodium through addition of their salts and amino acids from tryptone supplementation led to the expression of equivalent titres of recombinant proteins by E. coli (0.275 g/L), compared to that in LB media (0.296 g/L) and BMMY media (0.294 g/L) in shake flask culture. When this supplementation strategy was employed in a bioreactor system, we observed a significant increase in recombinant protein titre using the supplemented YSM (2.29 (±0.02) g/L) over that produced using LB media (1.29 (±0.09) g/L). This study demonstrates through highly sensitive compositional analysis and identification of supplementation strategies the potential to valorise spent media from yeast fermentations that underpin industrial processes of significant scale, creating a circular approach to waste stream management. Full article
Show Figures

Figure 1

13 pages, 1330 KiB  
Article
Promoting Optimal Habitat Availability by Maintaining Fine-Grained Burn Mosaics: A Modelling Study in an Australian Semi-Arid Temperate Woodland
by Ben J. French, Brett P. Murphy and David M. J. S. Bowman
Fire 2024, 7(6), 172; https://doi.org/10.3390/fire7060172 - 21 May 2024
Cited by 2 | Viewed by 1479
Abstract
The pyrodiversity–biodiversity (P–B) hypothesis posits that spatiotemporally variable fire regimes increase wildlife habitat diversity, and that the fine-grained mosaics resulting from small patchy fires enhance biodiversity. This logic underpins the patch mosaic burning (PMB) paradigm and reinforces the benefits of Indigenous fire management, [...] Read more.
The pyrodiversity–biodiversity (P–B) hypothesis posits that spatiotemporally variable fire regimes increase wildlife habitat diversity, and that the fine-grained mosaics resulting from small patchy fires enhance biodiversity. This logic underpins the patch mosaic burning (PMB) paradigm and reinforces the benefits of Indigenous fire management, which tends to promote pyrodiversity. However, tests of the P–B hypothesis and PMB paradigm are few. One of the most comprehensive field evaluations—a snapshot study of pre-existing fire mosaics in south-east Australian semi-arid mallee eucalypt woodlands—found little support. To explore the longer-term effects of fire mosaic grain size on habitat availability and biodiversity, we combined published data from the mallee study with a simple fire simulation. We simulated 500 years of landscape burning under different fire sizes. In the resulting mosaics, we assessed the proportional mixture and patch configuration of successional habitat states, then summarised habitat availability through time using a composite index based on the published fire history responses of 22 vertebrate taxa from the mallee study. Small fires formed fine-grained mosaics with a stable habitat mixture and with habitat diversity occurring at fine scales. Large fires formed coarse-grained mosaics with the opposite properties. The fine-grained mosaics maintained optimal habitat availability for vertebrate diversity over 500 years, while the fluctuating habitat mixture in the coarse-grained mosaics was unlikely to maintain maximum vertebrate diversity. Broadly, our results support the P–B hypothesis and justify further field-testing and evaluation of PMB programs to manage both pyrodiversity and biodiversity in the mallee and other flammable landscapes. Full article
(This article belongs to the Special Issue Effects of Fires on Forest Ecosystems)
Show Figures

Figure 1

15 pages, 4290 KiB  
Article
Compositional Variations between Adult and Infant Skin Microbiome: An Update
by Barry Murphy, Michael Hoptroff, David Arnold, Andrew Cawley, Emily Smith, Suzanne E. Adams, Alex Mitchell, Malcolm J. Horsburgh, Joanne Hunt, Bivash Dasgupta, Naresh Ghatlia, Samantha Samaras, Ashely MacGuire-Flanagan and Kirti Sharma
Microorganisms 2023, 11(6), 1484; https://doi.org/10.3390/microorganisms11061484 - 2 Jun 2023
Cited by 5 | Viewed by 3812
Abstract
Human skin and its commensal microbiome form the first layer of protection to the outside world. A dynamic microbial ecosystem of bacteria, fungi and viruses, with the potential to respond to external insult, the skin microbiome has been shown to evolve over the [...] Read more.
Human skin and its commensal microbiome form the first layer of protection to the outside world. A dynamic microbial ecosystem of bacteria, fungi and viruses, with the potential to respond to external insult, the skin microbiome has been shown to evolve over the life course with an alteration in taxonomic composition responding to altered microenvironmental conditions on human skin. This work sought to investigate the taxonomic, diversity and functional differences between infant and adult leg skin microbiomes. A 16S rRNA gene-based metataxonomic analysis revealed significant differences between the infant and adult skin groups, highlighting differential microbiome profiles at both the genus and species level. Diversity analysis reveals differences in the overall community structure and associated differential predicted functional profiles between the infant and adult skin microbiome suggest differing metabolic processes are present between the groups. These data add to the available information on the dynamic nature of skin microbiome during the life course and highlight the predicted differential microbial metabolic process that exists on infant and adult skin, which may have an impact on the future design and use of cosmetic products that are produced to work in consort with the skin microbiome. Full article
(This article belongs to the Section Molecular Microbiology and Immunology)
Show Figures

Figure 1

11 pages, 437 KiB  
Article
Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
by Vineeth Tatineni, Patrick J. O’Shea, Shreya Saxena, Atulya A. Khosla, Ahmad Ozair, Rupesh R. Kotecha, Xuefei Jia, Yasmeen Rauf, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom and Manmeet S. Ahluwalia
Cancers 2023, 15(11), 3015; https://doi.org/10.3390/cancers15113015 - 1 Jun 2023
Cited by 8 | Viewed by 3048
Abstract
Introduction: Traditionally, brain metastases have been treated with stereotactic radiosurgery (SRS), whole-brain radiation (WBRT), and/or surgical resection. Non-small cell lung cancers (NSCLC), over half of which carry EGFR mutations, are the leading cause of brain metastases. EGFR-directed tyrosine kinase inhibitors (TKI) have shown [...] Read more.
Introduction: Traditionally, brain metastases have been treated with stereotactic radiosurgery (SRS), whole-brain radiation (WBRT), and/or surgical resection. Non-small cell lung cancers (NSCLC), over half of which carry EGFR mutations, are the leading cause of brain metastases. EGFR-directed tyrosine kinase inhibitors (TKI) have shown promise in NSCLC; but their utility in NSCLC brain metastases (NSCLCBM) remains unclear. This work sought to investigate whether combining EGFR-TKI with WBRT and/or SRS improves overall survival (OS) in NSCLCBM. Methods: A retrospective review of NSCLCBM patients diagnosed during 2010–2019 at a tertiary-care US center was performed and reported following the ‘strengthening the reporting of observational studies in epidemiology’ (STROBE) guidelines. Data regarding socio-demographic and histopathological characteristics, molecular attributes, treatment strategies, and clinical outcomes were collected. Concurrent therapy was defined as the combination of EGFR-TKI and radiotherapy given within 28 days of each other. Results: A total of 239 patients with EGFR mutations were included. Of these, 32 patients had been treated with WBRT only, 51 patients received SRS only, 36 patients received SRS and WBRT only, 18 were given EGFR-TKI and SRS, and 29 were given EGFR-TKI and WBRT. Median OS for the WBRT-only group was 3.23 months, for SRS + WBRT it was 3.17 months, for EGFR-TKI + WBRT 15.50 months, for SRS only 21.73 months, and for EGFR-TKI + SRS 23.63 months. Multivariable analysis demonstrated significantly higher OS in the SRS-only group (HR = 0.38, 95% CI 0.17–0.84, p = 0.017) compared to the WBRT reference group. There were no significant differences in overall survival for the SRS + WBRT combination cohort (HR = 1.30, 95% CI = 0.60, 2.82, p = 0.50), EGFR-TKIs and WBRT combination cohort (HR = 0.93, 95% CI = 0.41, 2.08, p = 0.85), or the EGFR-TKI + SRS cohort (HR = 0.46, 95% CI = 0.20, 1.09, p = 0.07). Conclusions: NSCLCBM patients treated with SRS had a significantly higher OS compared to patients treated with WBRT-only. While sample-size limitations and investigator-associated selection bias may limit the generalizability of these results, phase II/III clinicals trials are warranted to investigate synergistic efficacy of EGFR-TKI and SRS. Full article
(This article belongs to the Special Issue Updates on Molecular Targeted Therapies for CNS Tumors)
Show Figures

Figure 1

18 pages, 3429 KiB  
Article
Cybersecurity in a Large-Scale Research Facility—One Institution’s Approach
by David S. Butcher, Christian J. Brigham, James Berhalter, Abigail L. Centers, William M. Hunkapiller, Timothy P. Murphy, Eric C. Palm and Julia H. Smith
J. Cybersecur. Priv. 2023, 3(2), 191-208; https://doi.org/10.3390/jcp3020011 - 16 May 2023
Cited by 4 | Viewed by 4355
Abstract
A cybersecurity approach for a large-scale user facility is presented—utilizing the National High Magnetic Field Laboratory (NHMFL) at Florida State University (FSU) as an example. The NHMFL provides access to the highest magnetic fields for scientific research teams from a range of disciplines. [...] Read more.
A cybersecurity approach for a large-scale user facility is presented—utilizing the National High Magnetic Field Laboratory (NHMFL) at Florida State University (FSU) as an example. The NHMFL provides access to the highest magnetic fields for scientific research teams from a range of disciplines. The unique challenges of cybersecurity at a widely accessible user facility are showcased, and relevant cybersecurity frameworks for the complex needs of a user facility with industrial-style equipment and hazards are discussed, along with the approach for risk identification and management, which determine cybersecurity requirements and priorities. Essential differences between information technology and research technology are identified, along with unique requirements and constraints. The need to plan for the introduction of new technology and manage legacy technologies with long usage lifecycles is identified in the context of implementing cybersecurity controls rooted in pragmatic decisions to avoid hindering research activities while enabling secure practices, which includes FAIR (findable, accessible, interoperable, and reusable) and open data management principles. The NHMFL’s approach to FAIR data management is presented. Critical success factors include obtaining resources to implement and maintain necessary security protocols, interdisciplinary and diverse skill sets, phased implementation, and shared allocation of NHMFL and FSU responsibilities. Full article
(This article belongs to the Topic Cyber Security and Critical Infrastructures)
Show Figures

Figure 1

14 pages, 1030 KiB  
Article
First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
by Vineeth Tatineni, Patrick J. O’Shea, Ahmad Ozair, Atulya A. Khosla, Shreya Saxena, Yasmeen Rauf, Xuefei Jia, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom and Manmeet S. Ahluwalia
Cancers 2023, 15(8), 2382; https://doi.org/10.3390/cancers15082382 - 20 Apr 2023
Cited by 13 | Viewed by 3405
Abstract
Introduction: Up to 50% of non-small cell lung cancer (NSCLC) harbor EGFR alterations, the most common etiology behind brain metastases (BMs). First-generation EGFR-directed tyrosine kinase inhibitors (EGFR-TKI) are limited by blood-brain barrier penetration and T790M tumor mutations, wherein third-generation EGFR-TKIs, like Osimertinib, have [...] Read more.
Introduction: Up to 50% of non-small cell lung cancer (NSCLC) harbor EGFR alterations, the most common etiology behind brain metastases (BMs). First-generation EGFR-directed tyrosine kinase inhibitors (EGFR-TKI) are limited by blood-brain barrier penetration and T790M tumor mutations, wherein third-generation EGFR-TKIs, like Osimertinib, have shown greater activity. However, their efficacy has not been well-studied in later therapy lines in NSCLC patients with BMs (NSCLC-BM). We sought to compare outcomes of NSCLC-BM treated with either first- or third-generation EGFR-TKIs in first-line and 2nd-to-5th-line settings. Methods: A retrospective review of NSCLC-BM patients diagnosed during 2010–2019 at Cleveland Clinic, Ohio, US, a quaternary-care center, was performed and reported following ‘strengthening the reporting of observational studies in epidemiology’ (STROBE) guidelines. Data regarding socio-demographic, histopathological, molecular characteristics, and clinical outcomes were collected. Primary outcomes were median overall survival (mOS) and progression-free survival (mPFS). Multivariable Cox proportional hazards modeling and propensity score matching were utilized to adjust for confounders. Results: 239 NSCLC-BM patients with EGFR alterations were identified, of which 107 received EGFR-TKIs after diagnosis of BMs. 77.6% (83/107) received it as first-line treatment, and 30.8% (33/107) received it in later (2nd–5th) lines of therapy, with nine patients receiving it in both settings. 64 of 107 patients received first-generation (erlotinib/gefitinib) TKIs, with 53 receiving them in the first line setting and 13 receiving it in the 2nd–5th lines of therapy. 50 patients received Osimertinib as third-generation EGFR-TKI, 30 in first-line, and 20 in the 2nd–5th lines of therapy. Univariable analysis in first-line therapy demonstrated mOS of first- and third-generation EGFR-TKIs as 18.2 and 19.4 months, respectively (p = 0.57), while unadjusted mPFS of first- and third-generation EGFR-TKIs was 9.3 and 13.8 months, respectively (p = 0.14). In 2nd–5th line therapy, for first- and third-generation EGFR-TKIs, mOS was 17.3 and 11.9 months, (p = 0.19), while mPFS was 10.4 and 6.08 months, respectively (p = 0.41). After adjusting for age, performance status, presence of extracranial metastases, whole-brain radiotherapy, and presence of leptomeningeal metastases, hazard ratio (HR) for OS was 1.25 (95% CI 0.63–2.49, p = 0.52) for first-line therapy. Adjusted HR for mOS in 2nd-to-5th line therapy was 1.60 (95% CI 0.55–4.69, p = 0.39). Conclusions: No difference in survival was detected between first- and third-generation EGFR-TKIs in either first or 2nd-to-5th lines of therapy. Larger prospective studies are warranted reporting intracranial lesion size, EGFR alteration and expression levels in primary tumor and brain metastases, and response rates. Full article
(This article belongs to the Special Issue Updates on Molecular Targeted Therapies for CNS Tumors)
Show Figures

Figure 1

25 pages, 4585 KiB  
Article
Unsupervised Diffusion and Volume Maximization-Based Clustering of Hyperspectral Images
by Sam L. Polk, Kangning Cui, Aland H. Y. Chan, David A. Coomes, Robert J. Plemmons and James M. Murphy
Remote Sens. 2023, 15(4), 1053; https://doi.org/10.3390/rs15041053 - 15 Feb 2023
Cited by 13 | Viewed by 3826
Abstract
Hyperspectral images taken from aircraft or satellites contain information from hundreds of spectral bands, within which lie latent lower-dimensional structures that can be exploited for classifying vegetation and other materials. A disadvantage of working with hyperspectral images is that, due to an inherent [...] Read more.
Hyperspectral images taken from aircraft or satellites contain information from hundreds of spectral bands, within which lie latent lower-dimensional structures that can be exploited for classifying vegetation and other materials. A disadvantage of working with hyperspectral images is that, due to an inherent trade-off between spectral and spatial resolution, they have a relatively coarse spatial scale, meaning that single pixels may correspond to spatial regions containing multiple materials. This article introduces the Diffusion and Volume maximization-based Image Clustering (D-VIC) algorithm for unsupervised material clustering to address this problem. By directly incorporating pixel purity into its labeling procedure, D-VIC gives greater weight to pixels corresponding to a spatial region containing just a single material. D-VIC is shown to outperform comparable state-of-the-art methods in extensive experiments on a range of hyperspectral images, including land-use maps and highly mixed forest health surveys (in the context of ash dieback disease), implying that it is well-equipped for unsupervised material clustering of spectrally-mixed hyperspectral datasets. Full article
(This article belongs to the Special Issue Theory and Application of Machine Learning in Remote Sensing)
Show Figures

Figure 1

Back to TopTop